首页> 美国卫生研究院文献>Stem Cells International >Promising Therapeutic Strategies for Mesenchymal Stem Cell-Based Cardiovascular Regeneration: From Cell Priming to Tissue Engineering
【2h】

Promising Therapeutic Strategies for Mesenchymal Stem Cell-Based Cardiovascular Regeneration: From Cell Priming to Tissue Engineering

机译:基于间充质干细胞的心血管再生的有前途的治疗策略:从细胞启动到组织工程。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The primary cause of death among chronic diseases worldwide is ischemic cardiovascular diseases, such as stroke and myocardial infarction. Recent evidence indicates that adult stem cell therapies involving cardiovascular regeneration represent promising strategies to treat cardiovascular diseases. Owing to their immunomodulatory properties and vascular repair capabilities, mesenchymal stem cells (MSCs) are strong candidate therapeutic stem cells for use in cardiovascular regeneration. However, major limitations must be overcome, including their very low survival rate in ischemic lesion. Various attempts have been made to improve the poor survival and longevity of engrafted MSCs. In order to develop novel therapeutic strategies, it is necessary to first identify stem cell modulators for intracellular signal triggering or niche activation. One promising therapeutic strategy is the priming of therapeutic MSCs with stem cell modulators before transplantation. Another is a tissue engineering-based therapeutic strategy involving a cell scaffold, a cell-protein-scaffold architecture made of biomaterials such as ECM or hydrogel, and cell patch- and 3D printing-based tissue engineering. This review focuses on the current clinical applications of MSCs for treating cardiovascular diseases and highlights several therapeutic strategies for promoting the therapeutic efficacy of MSCs in vitro or in vivo from cell priming to tissue engineering strategies, for use in cardiovascular regeneration.
机译:全世界慢性疾病中的主要死亡原因是缺血性心血管疾病,例如中风和心肌梗塞。最近的证据表明,涉及心血管再生的成人干细胞疗法代表了治疗心血管疾病的有前途的策略。由于其免疫调节特性和血管修复能力,间充质干细胞(MSC)是用于心血管再生的强大候选治疗性干细胞。但是,必须克服主要局限性,包括其在缺血性病变中的存活率非常低。已经进行了各种尝试来改善移植的MSC的不良存活和寿命。为了开发新的治疗策略,有必要首先鉴定用于细胞内信号触发或小生境活化的干细胞调节剂。一种有希望的治疗策略是在移植前用干细胞调节剂启动治疗性MSC。另一个是基于组织工程的治疗策略,涉及细胞支架,由生物材料(例如ECM或水凝胶)制成的细胞-蛋白质支架结构,以及基于细胞贴片和3D打印的组织工程。这篇综述着重于MSC在治疗心血管疾病方面的当前临床应用,并着重介绍了几种在体外或体内提高MSC治疗效果的治疗策略,从细胞引发到组织工程策略,用于心血管再生。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号